

References

S-141

1. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Hepatobiliary cancers. Version 3.2021.
2. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Neuroendocrine and adrenal tumors. Version 2.2021.
3. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Colon cancer. Version 2.2021.
4. Lurje I, Czigany Z, Bednarsch J, et al. Treatment strategies for hepatocellular carcinoma—A multidisciplinary approach. *Int J Mol Sci.* 2019;20(6):1465.
5. Zhao WJ, Zhu GQ, Wu YM, et al. Comparative effectiveness of radiofrequency ablation, surgical resection and transplantation for early hepatocellular carcinoma by cancer risk groups: Results of propensity score-weighted analysis. *Onco Targets Ther.* 2019;12:10389.
6. Chu HH, Kim JH, Kim PN, et al. Surgical resection versus radiofrequency ablation very early-stage HCC (≤ 2 cm single HCC): A propensity score analysis. *Liver Int.* 2019;39(12):2397-2407.
7. Zheng L, Zhang CH, Lin JY, et al. Comparative effectiveness of radiofrequency ablation vs. surgical resection for patients with solitary hepatocellular carcinoma smaller than 5 cm. *Front Oncol.* 2020;10:399.
8. Lin Y, Pan XB. Differences in survival between first-line radiofrequency ablation versus surgery for early-stage hepatocellular carcinoma: A population study using the surveillance, epidemiology, and end results database. *Med Sci Monit.* 2020;26:e921782.
9. Zhao WJ, Zhu GQ, Wu YM, et al. Comparative effectiveness of radiofrequency ablation, surgical resection and transplantation for early hepatocellular carcinoma by cancer risk groups: Results of propensity score-weighted analysis. *Onco Targets Ther.* 2019;12:10389-10400.
10. Yu C, Wu S, Zhao J, et al. Evaluation of efficacy, safety and treatment-related outcomes of percutaneous radiofrequency ablation versus partial hepatectomy for small primary liver cancer meeting the Milan criteria: A systematic review and meta-analysis of randomized controlled trials. *Clin Res Hepatol Gastroenterol.* 2020;44(5):718-732.
11. National Institute for Health and Care Excellence (NICE). Microwave ablation for treating liver metastases. 2016.
12. Glassberg MB, Ghosh S, Clymer JW, et al. Microwave ablation compared with hepatic resection for the treatment of hepatocellular carcinoma and liver metastases: A systematic review and meta-analysis. *World J Surg Oncol.* 2019;17(1):98.

13. Cui R, Yu J, Kuang M, et al. Microwave ablation versus other interventions for hepatocellular carcinoma: A systematic review and meta-analysis. *J Cancer Res Ther.* 2020;16(2):379-386.
14. Chong CCN, Lee KF, Cheung SYS, et al. Prospective double-blinded randomized controlled trial of Microwave versus RadioFrequency Ablation for hepatocellular carcinoma (McRFA trial). *HPB (Oxford).* 2020;22(8):1121-1127.
15. de Nucci G, Corte CD, Reati R, et al. Endoscopic ultrasound-guided radiofrequency ablation for hepatocellular carcinoma in cirrhosis: A case report test for efficacy and future perspectives. *Endosc Int Open.* 2020; 8(11):E1713-E17.
16. Kim HI, An J, Han S, et al. Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma : A network meta-analysis. *Clin Mol Hepatol.* 2023; 29(4):1013-1028.
17. Keshavarz P, Raman SS. Comparison of combined transarterial chemoembolization and ablations inpatients with hepatocellular carcinoma: A systematic review and meta-analysis. *Abdom Radiol (NY).* 2022; 47(3): 1009-1023.
18. Han Y, Zhao W, Wu M, Qian Y. Efficacy and safety of single- and multiple-antenna microwave ablation for the treatment of hepatocellular carcinoma and liver metastases: A systematic review and network meta-analysis. *Medicine (Baltimore).* 2022;101(51):e323